The U.S. Food and Drug Administration has made changes to the labels for fluoroquinolone antibacterial drugs administered by mouth or injection to address potential serious safety issues. The revised “boxed warning,” the agency’s strongest warning, notes that the drugs are “associated with disabling and potentially permanent side effects of the tendons, muscles, joints, nerves, and central nervous system” that can occur together. “Health care professionals should not prescribe systemic fluoroquinolones to patients who have other treatment options for acute bacterial sinusitis (ABS), acute bacterial exacerbation of chronic bronchitis (ABECB), and uncomplicated urinary tract infections (UTI) because the risks outweigh the benefits in these patients,” the agency states. For more, see the FDA Safety Announcement.

Related News Articles

Headline
A Health-ISAC (Information Sharing and Analysis Center) bulletin released Oct. 1 warns of a recently released LockBit 5.0 ransomware variant that poses a…
Headline
AHA Trustee Services will host a webinar Nov. 5 from 3-4:30 p.m. ET on the role of board leaders in creating productive and engaging board meetings and…
Headline
The federal government shutdown will continue as the Senate Oct. 3 failed to adopt a government funding deal. The latest attempt to pass the House-passed…
Perspective
Public
“Trust but verify” is a phrase often associated with President Reagan and the need to ensure that treaties enacted with the Soviet Union were being upheld.…
Headline
A JAMA study published yesterday analyzed the health characteristics of individuals projected to lose Medicaid coverage due to work requirements included in…
Headline
The Department of Health and Human Services announced Sept. 30 that it is doubling its funding for childhood cancer research from $50 million to $100 million…